DOCSLIB.ORG

WLI/100 11 November 2011 MARRAKESH AGREEMENT

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
WLI/100 11 November 2011 MARRAKESH AGREEMENT WORLD TRADE ORGANIZATION ORGANISATION MONDIALE DU COMMERCE ORGANIZACIÓN MUNDIAL DEL COMERCIO Reference: WLI/100 11 November 2011 MARRAKESH AGREEMENT ESTABLISHING THE WORLD TRADE ORGANIZATION DONE AT MARRAKESH ON 15 APRIL 1994 GENERAL AGREEMENT ON TARIFFS AND TRADE 1994 CERTIFICATION OF MODIFICATIONS AND RECTIFICATIONS TO SCHEDULE XXXVIII - JAPAN TRANSMISSION OF CERTIFIED TRUE COPY I have the honour to furnish herewith a certified true copy of the Certification of Modifications and Rectifications to Schedule XXXVIII - Japan, done 4 November 2011. Pascal Lamy Director-General 11-5834 WT/Let/835 Centre William Rappard Rue de Lausanne 154 Case postale CH - 1211 Genève 21 Téléphone: (+41 22) 739 51 11 Fax: (+41 22) 731 42 06 Internet: http://www.wto.org SCHEDULES OF TARIFF CONCESSIONS TO THE GENERAL AGREEMENT ON TARIFFS AND TRADE 1994 CERTIFICATION OF MODIFICATIONS AND RECTIFICATIONS SCHEDULE XXXVIII - JAPAN WHEREAS the CONTRACTING PARTIES to the General Agreement on Tariffs and Trade 1947 adopted, on 26 March 1980, a Decision on Procedures for Modification and Rectification of Schedules of Tariff Concessions (BISD 27S/25); WHEREAS in accordance with the provisions of the above-mentioned Decision, the draft containing modifications and rectifications to Schedule XXXVIII – Japan was communicated to all Members in document G/MA/TAR/RS/291 and G/MA/TAR/RS/291/Corr.1; IT IS HEREBY CERTIFIED that the modifications and rectifications to Schedule XXXVIII – Japan are established in conformity with the above-mentioned Decision. The annexed modifications and rectifications to the Schedule become effective in accordance with the notification to be given to that effect by the Government of Japan to the Director-General of the World Trade Organization upon completion of Japan’s internal procedures. This Certification is deposited with the Director-General of the World Trade Organization, who shall promptly furnish a certified true copy thereof to each Member of the World Trade Organization. It shall be registered in accordance with the provisions of Article 102 of the Charter of the United Nations. DONE at Geneva this fourth day of November, two thousand and eleven. Certified true copy: Director-General MODIFICATIONS AND RECTIFICATIONS TO SCHEDULE XXXVIII – JAPAN Schedule XXXVIII – Japan Page 5 WT/Let/835 SCHEDULE XXXVIII – Japan 4 November 2011 Schedule XXXVIII – Japan Page 6 WT/Let/835 PART I MOST-FAVOURED-NATION TARIFF SECTION II Other Products Mark the tariff item number 2843.29, 2910.20, 2921.51 with a letter “P” Schedule XXXVIII – Japan Page 7 WT/Let/835 Attachment to SCHEDULE XXXVIII – JAPAN Replace “Annexes IA, IB, IC and ID” in category (3) by “Annexes IA, IB, IC, ID and IE”. Replace “Annexes IA, IB, IC and ID” in category (4) by “Annexes IA, IB, IC, ID and IE”, and “Annex II” by “Annexes IIA and IIB”. Replace “Annexes IVA, IVB, IVC and IVD” in category (6) by “Annexes IVA, IVB, IVC, IVD and IVE”. Schedule XXXVIII – Japan Page 8 WT/Let/835 Insert the following Annex after Annex ID ANNEX IE Designated Pharmaceutical Active Ingredients (Additions by the fourth review) HS Subheading Description HS Subheading Description 2842.90 fermagate 2924.29 firategrast 2843.90 padeliporfin 2924.29 gabapentin enacarbil 2844.40 iodofiltic acid (123I) 2924.29 incyclinide 2904.10 eprodisate 2924.29 indantadol 2906.19 elocalcitol 2924.29 levomilnacipran 2909.30 terameprocol 2924.29 lisdexamfetamine 2916.19 peretinoin 2924.29 milveterol 2916.39 tarenflurbil 2924.29 ombrabulin 2918.19 bevirimat 2924.29 senicapoc 2919.00 fospropofol 2925.19 pomalidomide 2920.90 naproxcinod 2928.00 olesoxime 2921.19 tramiprosate 2928.00 sivifene 2922.19 afimoxifene 2928.00 tecovirimat 2922.19 ronacaleret 2928.00 tosedostat 2922.22 faxeladol 2928.00 vorinostat 2922.50 amibegron 2929.90 palifosfamide 2922.50 cinaciguat 2930.90 apremilast 2922.50 fasobegron 2930.90 camobucol 2923.10 choline fenofibrate 2930.90 dalcetrapib 2924.29 arbaclofen placarbil 2930.90 darinaparsin 2924.29 bedoradrine 2930.90 elesclomol 2924.29 carisbamate 2930.90 elsibucol 2924.29 emricasan 2930.90 ezatiostat 2924.29 eprotirome 2930.90 metenkefalin Schedule XXXVIII – Japan Page 9 WT/Let/835 HS Subheading Description HS Subheading Description 2930.90 monepantel 2933.39 befiradol 2930.90 odanacatib 2933.39 betrixaban 2930.90 salirasib 2933.39 daporinad 2930.90 succinobucol 2933.39 entinostat 2930.90 tipelukast 2933.39 goxalapladib 2931.00 amsilarotene 2933.39 imisopasem manganese 2932.19 eribulin 2933.39 levamlodipine 2932.19 pafuramidine 2933.39 levonadifloxacin 2932.29 omtriptolide 2933.39 migalastat 2932.99 arterolane 2933.39 motesanib 2932.99 cabazitaxel 2933.39 parogrelil 2932.99 celivarone 2933.39 pexacerfont 2932.99 dapagliflozin 2933.39 pimavanserin 2932.99 dexnebivolol 2933.39 pitolisant 2932.99 larotaxel 2933.39 rosonabant 2932.99 levonebivolol 2933.39 taranabant 2932.99 mifamurtide 2933.39 tropantiol 2932.99 vadimezan 2933.39 vapitadine 2933.19 eltrombopag 2933.39 volinaserin 2933.19 niraxostat 2933.49 almorexant 2933.19 palovarotene 2933.49 balamapimod 2933.19 totrombopag 2933.49 besifloxacin 2933.29 catramilast 2933.49 elvitegravir 2933.29 demiditraz 2933.49 ferroquine 2933.29 dulanermin 2933.49 intiquinatine 2933.29 lixisenatide 2933.49 nemonoxacin 2933.29 rolipoltide 2933.49 neratinib 2933.29 velafermin 2933.49 ozenoxacin 2933.39 alcaftadine 2933.49 rilapladib 2933.39 amifampridine 2933.49 tezampanel 2933.39 anamorelin 2933.49 veliflapon 2933.39 axitinib 2933.59 aderbasib Schedule XXXVIII – Japan Page 10 WT/Let/835 HS Subheading Description HS Subheading Description 2933.59 adipiplon 2933.79 mimopezil 2933.59 alogliptin 2933.79 orvepitant 2933.59 bafetinib 2933.79 pamapimod 2933.59 bosutinib 2933.79 paquinimod 2933.59 cariprazine 2933.79 perampanel 2933.59 casopitant 2933.79 rolapitant 2933.59 cediranib 2933.79 semagacestat 2933.59 cevipabulin 2933.79 voclosporin 2933.59 danusertib 2933.99 aleplasinin 2933.59 darapladib 2933.99 boceprevir 2933.59 dutacatib 2933.99 brivanib alaninate 2933.59 fimasartan 2933.99 denagliptin 2933.59 folitixorin 2933.99 denibulin 2933.59 linagliptin 2933.99 diaplasinin 2933.59 macitentan 2933.99 disitertide 2933.59 nilotinib 2933.99 epetirimod 2933.59 olaparib 2933.99 favipiravir 2933.59 otenabant 2933.99 flovagatran 2933.59 riociguat 2933.99 golotimod 2933.59 sitagliptin 2933.99 larazotide 2933.59 sotrastaurin 2933.99 laropiprant 2933.59 talmapimod 2933.99 lorcaserin 2933.59 talotrexin 2933.99 melogliptin 2933.59 ticagrelor 2933.99 obatoclax 2933.59 vicriviroc 2933.99 panobinostat 2933.69 imeglimin 2933.99 piragliatin 2933.79 aplaviroc 2933.99 pyronaridine 2933.79 bremelanotide 2933.99 rabeximod 2933.79 carmegliptin 2933.99 rotigaptide 2933.79 dovitinib 2933.99 rusalatide 2933.79 eribaxaban 2933.99 sofigatran 2933.79 ilepatril 2933.99 sotirimod Schedule XXXVIII – Japan Page 11 WT/Let/835 HS Subheading Description HS Subheading Description 2933.99 telaprevir 2934.99 bevasiranib 2933.99 tigapotide 2934.99 capeserod 2933.99 tiplasinin 2934.99 carfilzomib 2933.99 vabicaserin 2934.99 cenersen 2933.99 vernakalant 2934.99 conestat alfa 2934.10 capadenoson 2934.99 custirsen 2934.10 dasatinib 2934.99 derquantel 2934.10 inolitazone 2934.99 dexelvucitabine 2934.10 isavuconazole 2934.99 dilopetine 2934.10 isavuconazonium chloride2934.99 edoxaban 2934.10 lobeglitazone 2934.99 elacytarabine 2934.10 managlinat dialanetil 2934.99 esreboxetine 2934.10 masitinib 2934.99 fosalvudine tidoxil 2934.10 mirabegron 2934.99 fosaprepitant 2934.10 rosabulin 2934.99 ibodutant 2934.10 sodelglitazar 2934.99 idrabiotaparinux sodium 2934.10 teneligliptin 2934.99 imepitoin 2934.20 bentamapimod 2934.99 inakalant 2934.20 talarozole 2934.99 lancovutide 2934.99 aclidinium bromide 2934.99 lapaquistat 2934.99 adoprazine 2934.99 lensiprazine 2934.99 agatolimod 2934.99 lificiguat 2934.99 aleglitazar 2934.99 litenimod 2934.99 amolimogene bepiplasmid 2934.99 mipomersen 2934.99 anacetrapib 2934.99 nepidermin 2934.99 apadenoson 2934.99 omacetaxine mepesuccinate 2934.99 apilimod 2934.99 pardoprunox 2934.99 apricitabine 2934.99 pramiconazole 2934.99 azilsartan 2934.99 preladenant 2934.99 azilsartan medoxomil 2934.99 prinaberel 2934.99 bederocin 2934.99 quarfloxin 2934.99 beperminogene perplasmid 2934.99 radezolid Schedule XXXVIII – Japan Page 12 WT/Let/835 HS Subheading Description HS Subheading Description 2934.99 radiprodil 2935.00 nesbuvir 2934.99 raltegravir 2935.00 oglemilast 2934.99 regrelor 2935.00 pazopanib 2934.99 retosiban 2935.00 relacatib 2934.99 ridaforolimus 2935.00 resatorvid 2934.99 romidepsin 2935.00 tasisulam 2934.99 ropidoxuridine 2935.00 zibotentan 2934.99 sapacitabine 2940.00 ferric carboxymaltose 2934.99 saracatinib 2940.00 remogliflozin etabonate 2934.99 simotaxel 2940.00 sergliflozin etabonate 2934.99 taribavirin 3507.90 bucelipase alfa 2934.99 telatinib 3507.90 pegloticase 2934.99 trabedersen 3507.90 velaglucerase alfa 2934.99 trelanserin 3911.90 azoximer bromide 2934.99 velimogene aliplasmid 2934.99 viquidacin 2934.99 votucalis 2934.99 zotarolimus 2935.00 apricoxib 2935.00 begacestat 2935.00 belinostat 2935.00 brecanavir 2935.00 cevoglitazar 2935.00 drinabant 2935.00 giripladib 2935.00 ibipinabant 2935.00 laromustine 2935.00 lodenafil carbonate 2935.00 masilukast 2935.00 mavacoxib 2935.00 mirodenafil 2935.00 nelivaptan Schedule XXXVIII – Japan Page 13 WT/Let/835 Renumber Annex II as Annex IIA and amend the systematic name of the following prefix or suffix in Annex IIA as follows: Annex IIA Prefixes and Suffixes for Salts, Esters and Hydrates of INNs Preferred prefix or suffix
Load more

Recommended publications
  • BMC Pharmacology Biomed Central
    CORE Metadata, citation and similar papers at core.ac.uk Provided by Springer - Publisher Connector BMC Pharmacology BioMed Central Research article Open Access Pharmacological Properties of DOV 315,090, an ocinaplon metabolite Dmytro Berezhnoy†1, Maria C Gravielle†1, Scott Downing1, Emmanuel Kostakis1, Anthony S Basile2, Phil Skolnick2, Terrell T Gibbs1 and David H Farb*1 Address: 1Laboratory of Molecular Neurobiology, Department of Pharmacology & Experimental Therapeutics, Boston University School of Medicine, 715 Albany St., Boston, MA 02118, USA and 2DOV Pharmaceutical, Inc, 150 Pierce St., Somerset, NJ 08873-4185, USA Email: Dmytro Berezhnoy - [email protected]; Maria C Gravielle - [email protected]; Scott Downing - [email protected]; Emmanuel Kostakis - [email protected]; Anthony S Basile - [email protected]; Phil Skolnick - [email protected]; Terrell T Gibbs - [email protected]; David H Farb* - [email protected] * Corresponding author †Equal contributors Published: 13 June 2008 Received: 20 December 2007 Accepted: 13 June 2008 BMC Pharmacology 2008, 8:11 doi:10.1186/1471-2210-8-11 This article is available from: http://www.biomedcentral.com/1471-2210/8/11 © 2008 Berezhnoy et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Background: Compounds targeting the benzodiazepine binding site of the GABAA-R are widely prescribed for the treatment of anxiety disorders, epilepsy, and insomnia as well as for pre- anesthetic sedation and muscle relaxation. It has been hypothesized that these various pharmacological effects are mediated by different GABAA-R subtypes.
    [Show full text]
  • Modifications to the Harmonized Tariff Schedule of the United States to Implement Changes to the Pharmaceutical Appendix
    United States International Trade Commission Modifications to the Harmonized Tariff Schedule of the United States to Implement Changes to the Pharmaceutical Appendix USITC Publication 4208 December 2010 U.S. International Trade Commission COMMISSIONERS Deanna Tanner Okun, Chairman Irving A. Williamson, Vice Chairman Charlotte R. Lane Daniel R. Pearson Shara L. Aranoff Dean A. Pinkert Address all communications to Secretary to the Commission United States International Trade Commission Washington, DC 20436 U.S. International Trade Commission Washington, DC 20436 www.usitc.gov Modifications to the Harmonized Tariff Schedule of the United States to Implement Changes to the Pharmaceutical Appendix Publication 4208 December 2010 (This page is intentionally blank) Pursuant to the letter of request from the United States Trade Representative of December 15, 2010, set forth at the end of this publication, and pursuant to section 1207(a) of the Omnibus Trade and Competitiveness Act, the United States International Trade Commission is publishing the following modifications to the Harmonized Tariff Schedule of the United States (HTS) to implement changes to the Pharmaceutical Appendix, effective on January 1, 2011. Table 1 International Nonproprietary Name (INN) products proposed for addition to the Pharmaceutical Appendix to the Harmonized Tariff Schedule INN CAS Number Abagovomab 792921-10-9 Aclidinium Bromide 320345-99-1 Aderbasib 791828-58-5 Adipiplon 840486-93-3 Adoprazine 222551-17-9 Afimoxifene 68392-35-8 Aflibercept 862111-32-8 Agatolimod
    [Show full text]
  • Mitochondrial ADP/ATP Exchange Inhibition
    www.nature.com/scientificreports OPEN Mitochondrial ADP/ATP exchange inhibition: a novel off-target mechanism underlying ibipinabant- Received: 27 March 2015 Accepted: 27 August 2015 induced myotoxicity Published: 29 September 2015 Tom J. J. Schirris1,2, Tina Ritschel3, G. Herma Renkema2,4, Peter H. G. M. Willems2,5, Jan A. M. Smeitink2,4 & Frans G. M. Russel1,2 Cannabinoid receptor 1 (CB1R) antagonists appear to be promising drugs for the treatment of obesity, however, serious side effects have hampered their clinical application. Rimonabant, the first in class CB1R antagonist, was withdrawn from the market because of psychiatric side effects. This has led to the search for more peripherally restricted CB1R antagonists, one of which is ibipinabant. However, this 3,4-diarylpyrazoline derivative showed muscle toxicity in a pre-clinical dog study with mitochondrial dysfunction. Here, we studied the molecular mechanism by which ibipinabant induces mitochondrial toxicity. We observed a strong cytotoxic potency of ibipinabant in C2C12 myoblasts. Functional characterization of mitochondria revealed increased cellular reactive oxygen species generation and a decreased ATP production capacity, without effects on the catalytic activities of mitochondrial enzyme complexes I–V or the complex specific-driven oxygen consumption. Using in silico off-target prediction modelling, combined with in vitro validation in isolated mitochondria and mitoplasts, we identified adenine nucleotide translocase (ANT)-dependent mitochondrial ADP/ATP exchange as a novel molecular mechanism underlying ibipinabant-induced toxicity. Minor structural modification of ibipinabant could abolish ANT inhibition leading to a decreased cytotoxic potency, as observed with the ibipinabant derivative CB23. Our results will be instrumental in the development of new types of safer CB1R antagonists.
    [Show full text]
  • PHARMACEUTICAL APPENDIX to the TARIFF SCHEDULE 2 Table 1
    Harmonized Tariff Schedule of the United States (2020) Revision 19 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2020) Revision 19 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names INN which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service CAS registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known.
    [Show full text]
  • WO 2015/072852 Al 21 May 2015 (21.05.2015) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2015/072852 Al 21 May 2015 (21.05.2015) P O P C T (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 36/84 (2006.01) A61K 31/5513 (2006.01) kind of national protection available): AE, AG, AL, AM, A61K 31/045 (2006.01) A61P 31/22 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, A61K 31/522 (2006.01) A61K 45/06 (2006.01) BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (21) International Application Number: HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, PCT/NL20 14/050780 KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, (22) International Filing Date: MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, 13 November 2014 (13.1 1.2014) PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, (25) Filing Language: English TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (26) Publication Language: English (84) Designated States (unless otherwise indicated, for every (30) Priority Data: kind of regional protection available): ARIPO (BW, GH, 61/903,430 13 November 2013 (13. 11.2013) US GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, (71) Applicant: RJG DEVELOPMENTS B.V.
    [Show full text]
  • Potential Cannabis Antagonists for Marijuana Intoxication
    Central Journal of Pharmacology & Clinical Toxicology Bringing Excellence in Open Access Review Article *Corresponding author Matthew Kagan, M.D., Cedars-Sinai Medical Center, 8730 Alden Drive, Los Angeles, CA 90048, USA, Tel: 310- Potential Cannabis Antagonists 423-3465; Fax: 310.423.8397; Email: Matthew.Kagan@ cshs.org Submitted: 11 October 2018 for Marijuana Intoxication Accepted: 23 October 2018 William W. Ishak, Jonathan Dang, Steven Clevenger, Shaina Published: 25 October 2018 Ganjian, Samantha Cohen, and Matthew Kagan* ISSN: 2333-7079 Cedars-Sinai Medical Center, USA Copyright © 2018 Kagan et al. Abstract OPEN ACCESS Keywords Cannabis use is on the rise leading to the need to address the medical, psychosocial, • Cannabis and economic effects of cannabis intoxication. While effective agents have not yet been • Cannabinoids implemented for the treatment of acute marijuana intoxication, a number of compounds • Antagonist continue to hold promise for treatment of cannabinoid intoxication. Potential therapeutic • Marijuana agents are reviewed with advantages and side effects. Three agents appear to merit • Intoxication further inquiry; most notably Cannabidiol with some evidence of antipsychotic activity • THC and in addition Virodhamine and Tetrahydrocannabivarin with a similar mixed receptor profile. Given the results of this research, continued development of agents acting on cannabinoid receptors with and without peripheral selectivity may lead to an effective treatment for acute cannabinoid intoxication. Much work still remains to develop strategies that will interrupt and reverse the effects of acute marijuana intoxication. ABBREVIATIONS Therapeutic uses of cannabis include chronic pain, loss of appetite, spasticity, and chemotherapy-associated nausea and CBD: Cannabidiol; CBG: Cannabigerol; THCV: vomiting [8]. Recreational cannabis use is on the rise with more Tetrahydrocannabivarin; THC: Tetrahydrocannabinol states approving its use and it is viewed as no different from INTRODUCTION recreational use of alcohol or tobacco [9].
    [Show full text]
  • TE INI (19 ) United States (12 ) Patent Application Publication ( 10) Pub
    US 20200187851A1TE INI (19 ) United States (12 ) Patent Application Publication ( 10) Pub . No .: US 2020/0187851 A1 Offenbacher et al. (43 ) Pub . Date : Jun . 18 , 2020 ( 54 ) PERIODONTAL DISEASE STRATIFICATION (52 ) U.S. CI. AND USES THEREOF CPC A61B 5/4552 (2013.01 ) ; G16H 20/10 ( 71) Applicant: The University of North Carolina at ( 2018.01) ; A61B 5/7275 ( 2013.01) ; A61B Chapel Hill , Chapel Hill , NC (US ) 5/7264 ( 2013.01 ) ( 72 ) Inventors: Steven Offenbacher, Chapel Hill , NC (US ) ; Thiago Morelli , Durham , NC ( 57 ) ABSTRACT (US ) ; Kevin Lee Moss, Graham , NC ( US ) ; James Douglas Beck , Chapel Described herein are methods of classifying periodontal Hill , NC (US ) patients and individual teeth . For example , disclosed is a method of diagnosing periodontal disease and / or risk of ( 21) Appl. No .: 16 /713,874 tooth loss in a subject that involves classifying teeth into one of 7 classes of periodontal disease. The method can include ( 22 ) Filed : Dec. 13 , 2019 the step of performing a dental examination on a patient and Related U.S. Application Data determining a periodontal profile class ( PPC ) . The method can further include the step of determining for each tooth a ( 60 ) Provisional application No.62 / 780,675 , filed on Dec. Tooth Profile Class ( TPC ) . The PPC and TPC can be used 17 , 2018 together to generate a composite risk score for an individual, which is referred to herein as the Index of Periodontal Risk Publication Classification ( IPR ) . In some embodiments , each stage of the disclosed (51 ) Int. Cl. PPC system is characterized by unique single nucleotide A61B 5/00 ( 2006.01 ) polymorphisms (SNPs ) associated with unique pathways , G16H 20/10 ( 2006.01 ) identifying unique druggable targets for each stage .
    [Show full text]
  • Endocannabinoids in Body Weight Control
    pharmaceuticals Review Endocannabinoids in Body Weight Control Henrike Horn †, Beatrice Böhme †, Laura Dietrich and Marco Koch * Institute of Anatomy, Medical Faculty, University of Leipzig, 04103 Leipzig, Germany; [email protected] (H.H.); [email protected] (B.B.); [email protected] (L.D.) * Correspondence: [email protected]; Tel.: +49-341-97-22047 † These authors contributed equally. Received: 28 April 2018; Accepted: 28 May 2018; Published: 30 May 2018 Abstract: Maintenance of body weight is fundamental to maintain one’s health and to promote longevity. Nevertheless, it appears that the global obesity epidemic is still constantly increasing. Endocannabinoids (eCBs) are lipid messengers that are involved in overall body weight control by interfering with manifold central and peripheral regulatory circuits that orchestrate energy homeostasis. Initially, blocking of eCB signaling by first generation cannabinoid type 1 receptor (CB1) inverse agonists such as rimonabant revealed body weight-reducing effects in laboratory animals and men. Unfortunately, rimonabant also induced severe psychiatric side effects. At this point, it became clear that future cannabinoid research has to decipher more precisely the underlying central and peripheral mechanisms behind eCB-driven control of feeding behavior and whole body energy metabolism. Here, we will summarize the most recent advances in understanding how central eCBs interfere with circuits in the brain that control food intake and
    [Show full text]
  • Novel Approaches in Clinical Development of Cannabinoid Drugs
    Novel approaches in clinical development of cannabinoid drugs Linda Klumpers novel approaches in clinical development of cannabinoid drugs Novel approaches in clinical development of cannabinoid drugs proefschrift ter verkrijging van de graad van Doctor aan de Universiteit Leiden, op gezag van de Rector Magnificus prof. mr. C.J.J.M. Stolker, volgens besluit van het College voor Promoties, te verdedigen op dinsdag 21 januari 2014, klokke 16:15 uur door Linda Elvira Klumpers, geboren te Rotterdam in 1980 Promotiecommissie chapter i 7 Introduction to the endocannabinoid system as a target for drug development promotores Prof. dr. J.M.A. van Gerven chapter ii 49 Professor of Clinical Neuropsychopharmacology, Leiden University Medical Center Novel ∆9-tetrahydrocannabinol formulation Namisol® has bene- and Centre for Human Drug Research ficial pharmacokinetics and promising pharmacodynamic effects Prof. dr. A.F. Cohen Professor of Clinical Pharmacology, Leiden University Medical Center and Centre chapter iii 79 for Human Drug Research Manipulating brain connectivity with ∆9-tetrahydrocannabinol: a pharmacological resting state fmri study overige leden chapter iv 115 Prof. dr. P.H. van der Graaf Surinabant, a selective cb¡ antagonist, inhibits thc-induced Professor of Bio-pharmaceutical Sciences, Leiden University central nervous system and heart rate effects in humans Dr. J.T. Tamsma Internist and Medical Director of the Leiden University Medical Center chapter v 145 Prof. dr. R.F. Witkamp Peripheral selectivity of the novel cannabinoid receptor
    [Show full text]
  • 2 Spice English Presentation
    Spice Spice contains no compensatory substances Специи не содержит компенсационные вещества Spice is a mix of herbs (shredded plant material) and manmade chemicals with mind-altering effects. It is often called “synthetic marijuana” because some of the chemicals in it are similar to ones in marijuana; but its effects are sometimes very different from marijuana, and frequently much stronger. It is most often labeled “Not for Human Consumption” and disguised as incense. Eliminationprocess • The synthetic agonists such as THC is fat soluble. • Probably, they are stored as THC in cell membranes. • Some of the chemicals in Spice, however, attach to those receptors more strongly than THC, which could lead to a much stronger and more unpredictable effect. • Additionally, there are many chemicals that remain unidentified in products sold as Spice and it is therefore not clear how they may affect the user. • Moreover, these chemicals are often being changed as the makers of Spice alter them to avoid the products being illegal. • To dissolve the Spice crystals Acetone is used endocannabinoids synhtetic THC cannabinoids CB1 and CB2 agonister Binds to cannabinoidreceptor CB1 CB2 - In the brain -in the immune system Decreased avtivity in the cell ____________________ Maria Ellgren Since some of the compounds have a longer toxic effects compared to naturally THC, as reported: • negative effects that often occur the day after consumption, as a general hangover , but without nausea, mentally slow, confused, distracted, impairment of long and short term memory • Other reports mention the qualitative impairment of cognitive processes and emotional functioning, like all the oxygen leaves the brain.
    [Show full text]
  • Emerging Anti-Insomnia Drugs: Tackling Sleeplessness and the Quality of Wake Time
    REVIEWS Emerging anti-insomnia drugs: tackling sleeplessness and the quality of wake time Keith A. Wafford* and Bjarke Ebert‡ Abstract | Sleep is essential for our physical and mental well being. However, when novel hypnotic drugs are developed, the focus tends to be on the marginal and statistically significant increase in minutes slept during the night instead of the effects on the quality of wakefulness. Recent research on the mechanisms underlying sleep and the control of the sleep–wake cycle has the potential to aid the development of novel hypnotic drugs; however, this potential has not yet been realized. Here, we review the current understanding of how hypnotic drugs act, and discuss how new, more effective drugs and treatment strategies for insomnia might be achieved by taking into consideration the daytime consequences of disrupted sleep. Primary insomnia Humans spend approximately one-third of their lifetime Insomnia is defined as difficulty in initiating and/or Patients who suffer from sleeping, but we still know relatively little about why this maintaining sleep. The incidence of insomnia in the gen- sleeplessness for at least process is so critical for every living animal. Current eral population is between 10–30%, and approximately 1 month that cannot be thinking suggests that waking activity is relatively 50% of the cases complain of serious daytime conse- attributed to a medical, dynamic in terms of using the body’s resources: breaking quences, such as inability to concentrate, reduced energy psychiatric or an environmental cause (such as drug abuse or down proteins, gathering information and expending and memory problems. When this persists for more medications).
    [Show full text]
  • Cannabinoid Receptor Cannabinoid Receptor
    Cannabinoid Receptor Cannabinoid Receptor Cannabinoid receptors are currently classified into three groups: central (CB1), peripheral (CB2) and GPR55, all of which are G-protein-coupled. CB1 receptors are primarily located at central and peripheral nerve terminals. CB2 receptors are predominantly expressed in non-neuronal tissues, particularly immune cells, where they modulate cytokine release and cell migration. Recent reports have suggested that CB2 receptors may also be expressed in the CNS. GPR55 receptors are non-CB1/CB2 receptors that exhibit affinity for endogenous, plant and synthetic cannabinoids. Endogenous ligands for cannabinoid receptors have been discovered, including anandamide and 2-arachidonylglycerol. www.MedChemExpress.com 1 Cannabinoid Receptor Antagonists, Agonists, Inhibitors, Modulators & Activators (S)-MRI-1867 (±)-Ibipinabant Cat. No.: HY-141411A ((±)-SLV319; (±)-BMS-646256) Cat. No.: HY-14791A (S)-MRI-1867 is a peripherally restricted, orally (±)-Ibipinabant ((±)-SLV319) is the racemate of bioavailable dual cannabinoid CB1 receptor and SLV319. (±)-Ibipinabant ((±)-SLV319) is a potent inducible NOS (iNOS) antagonist. (S)-MRI-1867 and selective cannabinoid-1 (CB-1) receptor ameliorates obesity-induced chronic kidney disease antagonist with an IC50 of 22 nM. (CKD). Purity: >98% Purity: 99.93% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 1 mg, 5 mg Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg 2-Arachidonoylglycerol 2-Palmitoylglycerol Cat. No.: HY-W011051 (2-Palm-Gl) Cat. No.: HY-W013788 2-Arachidonoylglycerol is a second endogenous 2-Palmitoylglycerol (2-Palm-Gl), an congener of cannabinoid ligand in the central nervous system. 2-arachidonoylglycerol (2-AG), is a modest cannabinoid receptor CB1 agonist. 2-Palmitoylglycerol also may be an endogenous ligand for GPR119.
    [Show full text]